The short term effects of an AKT inhibitor (AZD5363) on biomarkers of the AKT pathway and anti-tumour activity in a breast cancer paired biopsy study
Phase of Trial: Phase II
Latest Information Update: 08 May 2017
At a glance
- Drugs AZD 5363 (Primary)
- Indications Breast cancer
- Focus Biomarker; Pharmacodynamics
- Acronyms STAKT
- 07 Jun 2017 Biomarkers information updated
- 03 May 2017 Status changed from active, no longer recruiting to completed.
- 01 Feb 2017 Planned primary completion date changed from 1 Feb 2017 to 20 Feb 2017.